Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab Plus SBRT in Malignant Mesothelioma
NCT03399552Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Dec 2017
- Primary completion
- Jan 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of avelumab in malignant mesothelioma, sponsored by Memorial Sloan Kettering Cancer Center. Started Dec 2017; status: completed.
02
Drugs
avelumab
03
Conditions
malignant mesothelioma
Beyond the preview
Go deeper on NCT03399552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03399552.